What is single-cell
RNA sequencing?

Single-cell RNA sequencing, commonly abbreviated scRNA-seq, is a family of experimental methods used to characterize RNA expression in individual cells. Instead of combining all cellular RNA into one average measurement, scRNA-seq produces cell-resolved expression profiles that help reveal biological heterogeneity.

This distinction is particularly important in hematopoiesis. Bone marrow contains hematopoietic stem cells, progenitors and many mature or developing immune and blood cell populations. Even cells carrying similar surface markers can differ in transcriptional state, cell-cycle activity or lineage-associated gene expression.

The measured transcriptome describes RNA molecules detected under a particular protocol and sampling condition. It does not measure every RNA molecule with perfect accuracy, directly quantify all proteins or establish the future fate of each analyzed cell.

The approach is especially powerful when combined with established hematopoietic knowledge, including hematopoietic stem cell biology and functional assays of differentiation and self-renewal.

From bone marrow
sample to data.

A typical hematopoietic scRNA-seq project begins with a clearly defined scientific question and carefully selected biological samples. Researchers may analyze total bone marrow, enriched CD34-positive human hematopoietic populations or experimentally isolated progenitor subsets.

Samples undergo preparation to obtain suitable cell suspensions or nuclei. Cells may then be captured by droplet-based platforms or distributed into individual wells, depending on the method. RNA is converted into sequencing-compatible libraries, which are subsequently processed to generate gene-by-cell count matrices.

Unique molecular identifiers (UMIs), used in many protocols, help reduce amplification-related counting bias. Cell barcodes allow sequencing reads to be associated with individual captured cells or nuclei. The resulting counts are computationally processed before biological interpretation.

Study quality begins before sequencing. Sample handling, viability, biological replication, processing time and enrichment strategy can alter which cell populations are captured. Poor experimental design cannot be fully corrected by downstream computational analysis.

Hematopoietic stem cells
are not identical.

Traditional hematopoietic models classify cells using surface-marker combinations and functional properties. In many studies, populations such as HSCs, multipotent progenitors and lineage-associated progenitors are enriched through flow cytometry before experimental analysis.

Single-cell transcriptomics has revealed substantial variation within these phenotypically defined compartments. Some cells express gene programs associated with stemness, while others show early transcriptional patterns linked to erythroid, megakaryocytic, myeloid or lymphoid differentiation.

In 2016, Nestorowa and colleagues generated a single-cell map of mouse hematopoietic stem and progenitor cell differentiation. The study helped illustrate how molecular expression states could be organized across early hematopoietic development.

The key insight is not that classical cell populations have become irrelevant. Rather, transcriptomic states reveal variations that may be missed when all cells within a sorted population are treated as equivalent.

How computational analysis
defines cell states.

After preprocessing and quality control, computational workflows often normalize gene-expression measurements, identify informative genes, reduce data dimensionality and group cells with similar expression profiles. Clustering provides a practical way to summarize heterogeneity within a large dataset.

Visualizations such as UMAP or t-SNE represent high-dimensional expression relationships in two dimensions. Nearby cells often share selected transcriptional characteristics, but distances in an embedding should not automatically be interpreted as exact biological distances or developmental timelines.

Researchers assign biological annotations using combinations of known markers, differential expression, reference datasets and other evidence. In hematopoiesis, lineage-associated transcriptional programs can help distinguish emerging erythroid, myeloid and lymphoid states.

A cluster is therefore a useful computational summary, not an automatic discovery of a new biological cell type. Biological replication, careful annotation and complementary experiments are essential for robust interpretation.

From branching trees
to continuums.

Classical hematopoietic diagrams frequently show a branching hierarchy: stem cells produce progressively restricted progenitors, which ultimately generate mature blood cells. This framework remains valuable for teaching developmental relationships and organizing experimental observations.

Single-cell studies have challenged the idea that every developmental transition passes through stable, clearly separated intermediate compartments. In 2015, Paul and colleagues identified marked transcriptional heterogeneity and lineage priming within mouse myeloid progenitors.

In 2017, Velten and colleagues integrated single-cell transcriptomic measurements with surface-marker and functional data in human hematopoietic progenitors. Their results supported a model of gradual lineage priming within a continuum of early hematopoietic states.

These observations do not prove that hematopoiesis has no developmental hierarchy whatsoever. Instead, they show that the molecular transitions between functional states can be more continuous, heterogeneous and context-dependent than simplified textbook diagrams suggest.

Can RNA data reveal
the direction of change?

Conventional scRNA-seq generally measures cells at one point in time. Researchers can arrange cells along an inferred developmental progression using pseudotime methods, which estimate the relative order of transcriptional states. Pseudotime does not directly measure real elapsed time.

RNA velocity methods extend this idea by modeling relationships between unspliced and spliced RNA molecules to estimate local trends in gene expression. In 2018, La Manno and colleagues introduced a foundational framework for estimating these dynamic tendencies from single-cell data.

The resulting directional estimates can suggest transitions between transcriptional states. However, RNA velocity depends on assumptions about RNA kinetics, measurement quality and modeling choices. It should not be treated as direct lineage tracing.

The limitations hidden
inside the dataset.

Although scRNA-seq provides remarkable cellular resolution, the data are shaped by technical and biological variation. Low-abundance transcripts may escape detection, stressed cells can change expression during processing, and two cells may occasionally be captured together as a doublet.

Batch effects can arise from different sample-processing times, sequencing runs, instruments, reagent lots or laboratory conditions. Computational integration helps compare datasets, but excessive correction can remove genuine biological differences.

Cell-cycle activity introduces another layer of variation. Proliferating progenitors may share expression signatures that reflect cell division rather than common lineage identity. Conversely, aggressive regression of cell-cycle signals can remove biologically relevant information.

An effective workflow evaluates these factors before cell types are assigned and biological conclusions are drawn. No single filtering threshold is universally suitable for every tissue, sample or sequencing protocol.

Why transcriptomics
needs other evidence.

RNA expression captures only one layer of cellular biology. A comprehensive understanding of hematopoietic identity may require protein measurements, chromatin accessibility, spatial information and functional assays. These measurements can help distinguish whether a molecular signature corresponds to a stable cell property, a temporary response or a technical artifact.

CITE-seq-style approaches combine RNA measurements with antibody-derived surface-protein information. Single-cell ATAC-seq examines chromatin accessibility, while spatial transcriptomic technologies investigate gene expression in anatomical context. Each approach provides information that conventional scRNA-seq cannot fully capture.

In hematopoiesis, functional tests remain essential. Colony assays provide information about selected progenitor behaviors, while transplantation experiments can evaluate durable repopulating potential in appropriate experimental models. These assays address biological function rather than only gene-expression similarity.

Integrating these different evidence types is especially valuable when studying the earliest hematopoietic populations, where transcriptional differences may be subtle and functional heterogeneity can be substantial.

Single-cell analysis
in disease research.

Hematologic diseases can alter the proportions, molecular programs and differentiation patterns of hematopoietic cells. Single-cell technologies provide a way to investigate these changes in heterogeneous tissue samples, including samples containing mixtures of normal, reactive and abnormal cells.

Research applications include studies of myeloid malignancies, marrow failure, inflammatory hematopoiesis, clonal hematopoiesis and changes in the bone marrow microenvironment. Single-cell data may help identify disease-associated transcriptional states or altered differentiation programs.

However, RNA expression alone does not reliably distinguish every malignant cell from a normal cell expressing similar genes. Integrating molecular genetics, immunophenotype, morphology and clinical information is often necessary for meaningful classification.

For a broader biological perspective, explore Hematologic Diseases and the Bone Marrow Microenvironment .

From cell atlases
to biotechnology.

Single-cell RNA sequencing has become an important tool for understanding how hematopoietic populations respond to experimental conditions. Its applications extend to stem cell culture, differentiation systems, cell manufacturing, drug-response research and the assessment of cellular heterogeneity in experimental products.

For example, researchers developing in vitro hematopoietic differentiation protocols can compare generated populations against reference transcriptomic atlases. This may reveal whether cultures resemble desired developmental states or contain unexpected alternative populations. Transcriptomic resemblance, however, is not sufficient to establish functional equivalence.

Emerging multimodal approaches combine transcriptional data with surface proteins, lineage information and spatial organization. These methods can improve biological interpretation and support the design of more informative experimental systems.

The contribution of scRNA-seq to modern hematopoiesis is therefore conceptual as well as technical. It has shown that blood formation cannot always be reduced to a small set of sharply separated developmental compartments. Instead, molecular cell states may vary continuously while still giving rise to recognizable functional lineages.

Future research will increasingly connect these descriptive maps with direct tests of cell fate, functional identity and causality. This combination of discovery and validation is central to applying single-cell technologies responsibly in biotechnology.